For the quarter ending 2026-03-31, BIO-B had -$23,200K decrease in cash & cash equivalents over the period. $78,100K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|
| Cash received from customers | 614,100 | 697,700 | 1,958,700 |
| Cash paid to suppliers and employees | 515,800 | 547,500 | 1,511,400 |
| Interest paid, net | 22,400 | 1,100 | 45,500 |
| Income tax payments, net | 11,000 | 7,300 | 54,300 |
| Investment proceeds and miscellaneous receipts, net | 33,300 | 18,300 | 62,700 |
| (payments for) proceeds from forward foreign exchange contracts, net | - | -38,100 | - |
| Proceeds from forward foreign exchange contracts, net | -52,800 | - | 42,900 |
| Net cash provided by operating activities | 108,100 | 164,900 | 367,300 |
| Capital expenditures | 30,000 | 45,800 | 111,800 |
| Proceeds from dispositions of property, plant and equipment | 100 | 0 | 100 |
| Proceeds from divestiture of a division | - | 0 | - |
| Payments for business acquisitions, net of cash received | - | 0 | 218,500 |
| Payments for acquired in-process research and development | - | 0 | 0 |
| Payments for purchases of marketable securities and investments | 226,100 | 138,800 | 530,500 |
| Proceeds from sale of debt securities, available-for-sale | 145,100 | 147,400 | 646,200 |
| Proceeds from maturities of marketable securities and investments | 17,700 | 3,000 | 59,000 |
| Net cash used in investing activities | -93,200 | -34,200 | -155,500 |
| Payments on long-term borrowings | 100 | 200 | 300 |
| Payments for debt issuance costs | - | 0 | 0 |
| Proceeds from issuance of common stock | -8,500 | - | 11,900 |
| Proceeds from issuance of common stock and from reissuance of treasury stock under the employee stock purchase plan and upon exercise of stock options | - | 15,800 | - |
| Tax payments from net share settlement | - | 400 | 2,600 |
| Payments for purchases of treasury stock | 47,800 | 0 | 295,500 |
| Payments of contingent consideration | - | 0 | - |
| Option premium proceeds for structured purchases of treasury stock | 500 | - | - |
| Net cash used in financing activities | -44,000 | 3,300 | -286,500 |
| Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash | - | -16,900 | - |
| Effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents | 22,800 | - | -16,900 |
| Cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect | -23,200 | 134,000 | -91,600 |
| Beginning cash, cash equivalents, and restricted cash | 532,200 | 91,600 | 489,800 |
| Ending cash, cash equivalents, and restricted cash | 509,000 | 134,000 | 398,200 |
BIO-RAD LABORATORIES, INC. (BIO-B)
BIO-RAD LABORATORIES, INC. (BIO-B)